NEW AMBRX BIOPHARMA INC (AMAM)
US6418711080 - Common Stock
| MRQ (2023-9-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 225.30M | 55.60M | 170.10M | 90.50M | 15.50M | |||
| Marketable Securities | 0.00 | 28.90M | N/A | N/A | N/A | |||
| Receivables | 2.40M | 2.10M | 1.30M | 1.00M | 1.40M | |||
| Other Current Assets | 6.20M | 4.10M | 5.40M | 1.60M | 1.30M | |||
| Total Current Assets | 233.80M | 90.60M | 176.80M | 93.10M | 18.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 12.60M | 14.00M | 15.70M | 3.50M | 5.00M | |||
| Investments And Advances | 0.00 | 16.80M | N/A | N/A | N/A | |||
| Intangibles | 24.80M | 25.30M | 36.00M | 36.80M | 38.30M | |||
| Other Non-Current Assets | 300.00K | 300.00K | 500.00K | 600.00K | 300.00K | |||
| Total Non-Current Assets | 37.70M | 56.40M | 52.20M | 40.90M | 43.50M | |||
| TOTAL ASSETS | 271.50M | 147.00M | 229.00M | 134.00M | 61.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 12.70M | 13.00M | 15.00M | 4.00M | 5.30M | |||
| Accounts Payable | 5.10M | 3.20M | 5.30M | 2.80M | 5.40M | |||
| Other Current Liabilities | 400.00K | 400.00K | 4.30M | 6.50M | 4.20M | |||
| Total Current Liabilities | 18.30M | 16.70M | 24.60M | 13.30M | 14.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | 900.00K | 900.00K | 900.00K | 900.00K | 800.00K | |||
| Other Non-Current Liabilities | 10.00M | 11.60M | 13.60M | 5.00M | 10.00M | |||
| Total Non-Current Liabilities | 10.80M | 12.40M | 14.50M | 7.10M | 13.40M | |||
| TOTAL LIABILITIES | 29.10M | 29.10M | 39.10M | 20.40M | 28.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -347.70M | -291.60M | -213.60M | -145.60M | -129.00M | |||
| Additional Paid In Capital | 590.90M | 410.80M | 404.40M | 6.80M | 163.30M | |||
| Minority Interest | N/A | 0.00 | 210.00K | 2.60M | 4.85M | |||
| Common Shares | 0.00 | 0.00 | 0.00 | 253.00M | 0.00 | |||
| Other Shareholders' Equity | -800.00K | -1.30M | -800.00K | -700.00K | -800.00K | |||
| Shares Outstanding | 126.00M | 270.50M | 270.10M | 263.70M | 263.70M | |||
| Tangible Book Value per Share | 1.73 | 0.34 | 0.57 | -0.67 | -0.02 | |||
| Total Shareholders' Equity | 242.40M | 117.90M | 190.00M | 113.60M | 33.40M | |||
| TOTAL LIABILITIES AND EQUITY | 271.50M | 147.00M | 229.00M | 134.00M | 61.70M | |||
| Statistics | ||||||||
| Current Ratio | 12.78 | 5.43 | 7.19 | 7.00 | 1.22 | |||
| Return On Assets (ROA) | -30.43% | -53.06% | -29.73% | -12.34% | -32.51% | |||
| Return On Equity (ROE) | -34.09% | -66.16% | -35.83% | -14.56% | -60.06% | |||
All data in USD